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a b s t r a c t
The ability of phosphonium cations to act as intracellular transport vectors is well-established. Phospho-
nioalkylthiosulfate zwitterions, and u-thioacetylalkylphosphonium salts, which act as 'masked thiolate'
ligands, are useful precursors for the formation of phosphonium-functionalised gold nanoparticles,
enabling the nanoparticles tobe transported into cells for diagnostic and therapeutic purposes. In this study
we have completed cytotoxicity studies of u-thioacetylpropylphosphonium salts derived from triphenyl-
phosphine and tri(4-ﬂuorophenyl)phosphine, which show that the compounds are only toxic towards PC3
prostate cancer cells at high concentrations and at prolonged incubation periods and display IC50 values of
67mMand252 mMrespectively, signiﬁcantlyhigher than those of other phosphoniumsalts.MALDI-TOF-MS
has been used to investigate the uptake of the compounds by PC3 cells and to quantify detectable levels of
the compounds inside the cells. The structures of u-thioacetylpropyl(tri-4-ﬂuorophenyl) phosphonium
bromide and the corresponding tri(4-ﬂuorophenyl)phosphoniopropylthiosulfate zwitterion have been
investigated by single crystal X-ray crystallography. The results show that molecules of the zwitterion are
held together through an extensive array of electrostatic and non-covalent interactions. The unit cell of u-
thioacetylpropyl(tri-4-ﬂuorophenyl)phosphonium bromide contains eight cations together with eight
bromide anions and twowaters of crystallisation, all held together through a complex network of hydrogen
bonds. The differences in themolecular packing of the two compoundsmayaccount for the lower solubility
of the zwitterion in aqueous solutions, compared with that of the phosphonium salt.
© 2016 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Phosphonium compounds are versatile species that ﬁnd appli-
cation in diverse ﬁelds ranging from synthetic reagents, e.g., in the
Wittig reaction, to ﬂame retardant materials and ionic liquids. A
remarkable feature of phosphonium compounds is their ability to
cross cell membranes and be concentrated inside mitochondria
without the need for a transporter protein or chaperone [1].
In recent years, it has become evident that mitochondrial
dysfunction contributes to a range of human diseases, including
cancer and neurodegenerative disorders, and there has been an in-
crease in effort made towards the development of pharmacological
strategies which can transport molecules into this organelle [2].
Consequently, phosphoniumgroupshave been conjugated to awide
variety of species including metal complexes [3], dendrimers [4],
liposomes [5] andnanoparticles [6e8],with aview to their potential
applications inmitochondria-targeteddiagnostics and therapeutics.
Previously we have prepared a series of phosphonioalkylth-
iosulfate zwitterions [9], and u-thioacetylalkylphosphonium salts
[10], which act as 'masked thiolate' ligands; under reductive con-
ditions, the thiosulfate and thioacetate groups cleave, generating
phosphonioalkylthiolate anions that can attach to the surface of gold
nanoparticles, generating phosphonioalkylthiolate-functionalised
gold nanoparticles [7,8]. The phosphonium-functionalised gold
nanoparticles can be isolated and are readily taken-up by the
mitochondria of cancer cells [8,11].
It has been demonstrated that the rate and extent of uptake of
phosphonium compounds in vitro are affected by the hydrophobicity
of the compound [12]. The addition of ﬂuorine has been routinely
applied in medicinal chemistry to modify the physiochemical prop-
erties of drugs; ﬂuorine has been incorporated into compounds to
improvemetabolic stability, lipophilicity and binding afﬁnity with an
* Corresponding authors.
E-mail addresses: n.a.cross@shu.ac.uk (N.A. Cross), n.bricklebank@shu.ac.uk
(N. Bricklebank).
Contents lists available at ScienceDirect
European Journal of Medicinal Chemistry
journal homepage: http: / /www.elsevier .com/locate/ejmech
http://dx.doi.org/10.1016/j.ejmech.2016.08.025
0223-5234/© 2016 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
European Journal of Medicinal Chemistry 125 (2017) 528e537
overall target to increase the bioavailability of the product [13].
Furthermore phosphonium compounds labelled with radioactive 18F
have been developed as a new class of lipophilic positron emission
tomography (PET) radiotracers [14]. As part of our investigations into
the chemistry and biology of phosphonium compounds and
phosphonium-functionalised nanomaterials, we report herein the
cellular-uptake and cytotoxicity data for the u-thio-
acetylalkylphosphonium derivatives of triphenyl- and 4-
ﬂuorophenyl-phosphine together with structural investigations of
the tri(4-ﬂuororophenyl)phosphoniopropyl thiosulfate zwitterion
andu-thioacetylalkyl(tri-4-ﬂuorophenyl)phosphoniumbromidesalt.
2. Results
2.1. Cytotoxicity of phosphonioalkyl-thiosulfate zwitterions and
-thioacetate salts
Preliminary investigations into the cytotoxicity of 1e4 indicated
that the thiosulfate zwitterions, 1 and 3, are non-toxic. The thio-
sulfate zwitterions are only sparingly soluble in water, DMSO,
methanol and biological media; however, thioacetate salts 2 and 4
are soluble in aqueous solvent systems and we have been able to
determine the cellular uptake and cell viability of these compounds.
The cytotoxicity of compounds 2 and 4 against the PC3 prostate
cell cancer line was determined using the CellTitre-Glo® assay,
which uses luminescence to determine the number of viable cells
based on a quantiﬁcation of ATP levels. The data are presented in
Fig.1. The data show that compounds 2 and 4 are only toxic towards
PC3 cells at high concentrations and at prolonged incubation pe-
riods, with calculated IC50 values of 67 mM and 252 mM for 2 and 4,
respectively, at 72 hours. The IC50 values reported here are signif-
icantly higher than those of other phosphonium-containing mol-
ecules. Millard and co-workers have determined the cytotoxicity of
33 phosphonium compounds, all containing the triphenylphos-
phonium moiety linked to different chemical groups, in ﬁve
different cell lines [15]. Their most toxic compound, TP 731 (5), has
an IC50 in PC3 cells of 0.4 mM at 72 h, ca.160-fold more toxic than 2,
whilst the least toxic compound TP 764 (6) has an IC50 of 8 mM at
72 h, which is still 16-fold more toxic than 2, indicating that the u-
thioacetylpropyltriphenylphosphonium salts investigated in this
study are comparatively non-toxic towards cells.
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2.2. Use of MALDI-TOF-MS to study the uptake of u-
thioacetylalkylphosphonium salts by PC3 cancer cells
Matrix-assisted laser desorption/ionisation time-of-ﬂight mass
spectrometry (MALDI-TOF-MS) is a widely used analytical tool due
to its high-speed analysis, simplicity and excellent sensitivity.
Although MALDI-TOF-MS has transformed the analysis of large
biomolecules, its application to small molecules with molar masses
typically below 1000 Da has lagged behind. Demand for high-
throughput methods in drug discovery and biotechnology has
driven the utilisation of MALDI-TOF-MS in small molecule analysis
[16]. There are two reports on the use of MALDI-TOF-MS to quantify
the uptake of phosphonium compounds in cells. Rideout and col-
leagues were the ﬁrst to demonstrate the quantitative analysis of
phosphonium cations by MALDI-TOF-MS, showing that
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Fig. 1. PC3 cells treated with u-thioacetylalkylphosphonium salts (a) 2, and (b) 4, for
24, 48 and 72 h. Cell proliferation was determined by the CellTiter-Glo™ luminescent
cell viability assay kit. Data are expressed as a percentage of live cells normalised to
control, mean ± SD (n ¼ 12).
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tetraphenylphosphonium salts were taken-up in sub-femtomole
amounts in carcinoma cell lines [17]. Cheng and co-workers re-
ported the uptake of a range of phosphonium cations in the sub-
femtomole region by C6 rat glioma cells using MALDI-TOF-MS
[18]. In MALDI experiments, a matrix is incorporated into the
sample preparation stage to provide efﬁcient desorption and soft
ionisation of the analyte. The previous studies of phosphonium
compounds in cells used aCHCA (a-cyano-4-hydroxycinnamic
acid) as the matrix, the most common matrix used for the anal-
ysis of small molecules [16]. However, aCHCA was unsuitable for
the analysis of 2 because the molecular ion peak [M]þ is atm/z 379
which coincides with the aCHCA dimer peak [2 M þ H]þ at m/z
379. This presented a problem for quantiﬁcation work, as the peak
area would be either under- or over-estimated making the results
unreliable. Consequently DHB (2,5-dihydroxybenzoic acid), which
is the other matrix commonly used for the analysis of small organic
molecules [16], was employed for the analysis of 2. In order to
improve experimental reproducibility, an internal standard is
usually employed for theMALDI analysis of lowermolecular weight
molecules. In this study tetraphenylphosphonium bromide was
used because of its chemical similarity to 2 and 4; Fig. 2 shows the
ion intensity ratio of the product ionm/z 379 andm/z 433 for 2 and
4, respectively, against [Ph4P]Br at m/z 339. The calibration curves
(Fig. 3) demonstrate that the ion intensity ratio increases with
increasing concentration of 2 and 4. The MALDI-TOF-MS spectra in
Fig. 4 show the ion intensities of 2 at m/z 379 and the internal
standard at m/z 339 at each incubation time point. Similar data
were obtained for 4, conﬁrming that these u-thio-
acetylalkylphosphonium salts are readily taken-up by cells. The up-
take of 2 and 4 as a function of time is illustrated in Fig. 5 and shows
that the compounds exhibit different uptake proﬁles. Compound 2
is rapidly taken-up by the cells, reaching a maximum uptake at
10 min, which then drops slightly, reaching a plateau after 30 min.
In contrast, 4 reaches a maximum uptake three times slower than
that of 2 before declining and reaching a plateau after 90 min.
Similar differences have been noted in the up-take and
accumulation of tetraphenylphosphonium and 4-
ﬂuorophenyl(triphenyl)phosphonium cations by C6 glioma cells
[18].
2.3. Structural studies of the tri(4-ﬂuororophenyl)
phosphoniopropyl thiosulfate zwitterion (3) and the u-
thioacetylpropyl(tri-4-ﬂuorophenyl)phosphonium bromide salt (4)
Given the differences in the solubility of the phosphoniu-
malkylthiosulfate zwitterions compared to the thioacetate salts,
and the differences in the IC50 and cellular up-take of thioacetate
derivatives 2 and 4, we decided to investigate the crystal structures
of the tri(4-ﬂuorophenyl)phosphonium compounds 3 and 4. The
structures of few other organic thiosulfate zwitterions have been
described in the literature. We have previously reported
the structure of 1, together with that of the tribu-
tylphosphoniothiosulfate zwitterion (7) [9]. The only other crys-
tallographically characterised thiosulfate zwitterions are the
ammonium derivative S-[4-(trimethylammonio)phenyl]thiosulfate
(8) [19], and the triphenylarsoniopropyl thiosulfate zwitterion [20].
P SSO3
SSO3Me3N
7 8
Single crystals of 3 and 4 were grown by slow diffusion of
diethyl ether into dichloromethane solutions of each compound,
resulting in the formation of colourless crystals. The molecular
structure of 3 is shown in Fig. 6 and selected bond lengths and
angles in Table 1. Zwitterion 3 displays the expected tetrahedral
geometry around the phosphorus atoms with a mean CePeC bond
angle of 109.46(2). The corresponding values for the triphenyl and
tributyl analogues 1 and 7 are 109.47(11) and 109.47(17)
Fig. 2. MALDI-TOF-MS spectrum of the internal standard [Ph4P]Br (IS), 2 and 4 at the same concentration of 100 mM. Peaks noted correspond to[Ph4P]Br atm/z 339.12, 2 [M]
þ atm/z
379.12,and 4 [M]þ at m/z 433.09.
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respectively. The bond lengths and angles in the aryl rings are
unremarkable and the CeF bonds [mean length 1.361(6) Å] are
similar to those in the parent phosphine, (4-FC6H4)3P [mean length
1.366(6) Å] [21].
The SeO bonds in the thiosulfate group of compound 3 are all
similar, with a mean length of 1.439(4)Å [c.f. 1.4478(19) Å in 1 and
1.440(3) Å in 7], indicative of multiple bond character. The mean
OeSeO angle [113.5(3)] is consistent with those in other thiosul-
fate ions. The SeS bond length [2.1076(19)Å], is slightly shorter than
that of 1 [2.1117(9) Å], and longer than that in 7 [2.1030(14) Å], but
all are longer than the established length of a single SeS bond
[2.05 Å] [22]. The ammonium thiosulfate zwitterion 8 has an SeS
bond length of 2.1137(7) Å, similar to those of 1,3 and 7, but all are
appreciably shorter than the SeS bond in the monoanion of thio-
sulfuric acid, HSSO3
 [2.155] [23]. The lengthening of the SeO and
SeS bonds in the zwitterions is consistent with the delocalisation of
the negative charge across the entire thiosulfate group. Further-
more, the longer and weaker SeS bond of the phosphonium
zwitterions expedites the dissociation of the thiosulfate group with
the concomitant formation of the corresponding thiolate ionwhich
is a key step in the application of these compounds in the synthesis
of metal nanoparticles.
Within the crystal lattice the zwitterions are held together in a
head-to-tail manner, by hydrogen-bonding interactions between
the sulfate oxygens and the phenyl hydrogens (Fig. 7). Analysis of
the supramolecular structure reveals face-to-face phenyl embrace
interactions between aryl groups on adjacent molecules [24]. The
centroid-centroid distance between these two rings is 3.65 Åwhich
ﬁts well with the interplanar spacing observed in stacked arenes
which lie in the range between 3.6 and 3.8 Å [25]. The molecules
also display intramolecular CeF/.H hydrogen bonding interactions
between adjacent aryl rings, with an F/H distance of 2.409 Å. The
nature of CeF/H interactions is the subject of some debate [26,27].
Nonetheless, the interactions in 3 are shorter than the sum of the
van der Waals radii for hydrogen and ﬂuorine (2.67 Å) and are
similar in length to those found in other ﬂuorine-containing
organic molecules [27].
The molecular structure of u-thioacetylpropyl(tri-4-
ﬂuorophenyl)phosphonium bromide 4 is shown in Fig. 8 and
selected bond lengths and angles in Table 2. The asymmetric unit
Fig. 3. MALDI-TOF-MS Calibration curve for u-thioacetylalkylphosphonium salts (a) 2, and (b) 4. The graph shows that between 0 and 1000 nM, compounds 2 and 4 have a linear
response of R2 ¼ 0.9949 and 0.9879 respectively. The insert in each graph shows the expanded region between 0 and 500 nM for each compound.
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contains two crystallographically independent phosphonium cat-
ions, two bromide anions and two molecules of water of crystal-
lisation. The bond lengths and angles of the two cations within the
unit cell are very similar and lie within the normal range. The
compound displays the expected tetrahedral geometry around the
phosphorus atom with a mean bond angle of 109.47(3), identical
to that in zwitterion 3. The CeF bonds in the phenyl rings lie in the
range 1.352(6) - 1.371(5), similar to those in 3 and those in the
parent phosphine, which have an average length of 1.366(6) Å [21].
The CeS and CeO bond lengths of the thioacetate group in 4 are
similar to the expected distances for CeS single and C]O bonds,
ca.1.8 Å and 1.2 Å respectively [22], and are similar to the compa-
rable bonds in u-thioacetylpropyl(triphenyl)arsonium bromide
[which has CeS bond lengths of 1.806(3)Å, 1.777(3) Å and a C]O
bond length of 1.204(3) Å] [20]. Similarly, dimethylmonothiocar-
bonate, CH3OC(S)CH3, has CeS bond lengths of 1.791(2)Å,1.759(1) Å
and a C]O bond length of 1.195(2) Å [28].
The molecular packing displays some interesting features
(Fig. 9); the unit cell contains eight cations together with eight
bromide anions and water molecules which are associated with the
Fig. 4. Representative MALDI-TOF-MS spectra for time course of uptake of 2 in PC3 cells. PC3 cells were treated with 5 mM 2 and incubated for 5e90 min. Peaks corresponding to
[M]þ of 2 atm/z 379, the matrix a-CHCA atm/z 136.99 and internal standard atm/z 339.01 were observed. The control sample was PC 3 cells, internal standard and matrix alone. No
[M]þ peak for 2 was observed in the control which conﬁrmed the absence of this compound in the untreated sample.
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bromide ions, all held together through a complex network of
hydrogen bonds (Fig. 10) and intermolecular interactions between
the different species. The structural parameters for the principal
hydrogen bond interactions are presented in Table 3. The cations
also display intramolecular CeF/.H interactions which lie in the
range 2.639e2.670 Å. These distances are slightly longer than those
observed in zwitterion 3, and are close to the sum of the van der
Waals radii of ﬂuorine and hydrogen (2.67 Å), but are comparable
with the distances observed in other organoﬂuorine compounds.
3. Discussion
There is growing interest in the use of phosphonium com-
pounds as a means of transporting a range of molecular and
macromolecular and nanoscale materials into cells for diagnostic
and therapeutic applications. Phosphonioalkylthiosulfate zwitter-
ions and u-thioacetylalkylphosphonium salts have been shown to
be useful precursors for the synthesis of phosphonium-
functionalised gold nanoparticles. The data reported here provide
an insight into the biological behaviour of the zwitterions and salts
themselves. The IC50 values of u-thioacetylalkylphosphonium salts
2 and 4 show the compounds to have low cytotoxicity compared to
other phosphonium salts.
A notable feature is the difference in the IC50 values of 2 and 4,
67 mM and 252 mM respectively after 72 hours. The only difference
between the two compounds is the replacement of hydrogen in the
para position of the phenyl rings with ﬂuorine. This slight
Fig. 5. The uptake and accumulation of (a) 2 and (b) 4 by PC3 cells as a function of
time; PC3 cells were treated with 5 mM 2 or 4 and incubated between 0 and 90 min.
Concentrations were determined from the calibration curve. Each sample was analysed
in triplicate from three independent experiments.
Fig. 6. Ortep representation of the molecular structure of 3. Thermal ellipsoids are
drawn at 50% probability level.
Table 1
Selected Bond Lengths (Å) and angles () in 3.
P1eC1 1.794(5) P101eC101 1.791(5)
P1eC7 1.785(5) P101eC107 1.788(5)
P1eC13 1.798(5) P101eC113 1.784(5)
P1eC19 1.803(4) P101eC119 1.792(5)
S1eC21 1.808(5) S101eC121 1.824(5)
S1eS2 2.1221(19) S101eS102 2.0930(18)
S2eO1a 1.394(4) S102eO101 1.442(3)
S2eO2a 1.436(4) S102eO102 1.444(3)
S2eO3a 1.468(4) S102eO103 1.447(3)
C1eP1eC7 109.0(2) C101eP101eC107 108.3(2)
C1eP1eC13 109.2(2) C101eP101eC113 109.5(2)
C1eP1eC19 110.3(2) C101eP101eC119 109.9(2)
C7eP1eC13 107.5(2) C107eP101eC113 108.9(2)
C7eP1eC19 110.0(2) C107eP101eC119 110.4(2)
C13eP1eC19 110.7(2) C113eP101eC119 109.8(2)
C20eC19eP1 114.6(3) C120eC119eP101 114.0(3)
C20eC21eS1 114.6(3) C120eC121eS101 111.5(3)
C21eS1eS2 101.88(19) C121eS101eS102 100.27(17)
O1a-S2-O2a 116.6(3) O101eS102eO102 113.9(2)
O1a-S2-O3a 113.3(3) O101eS102eO103 114.9(2)
O2a-S2-O3a 110.1(3) O102eS102eO103 112.2(2)
O1a-S2-S1 107.1(2) O101eS102eS101 101.24(15)
O2a-S2-S1 103.23(19) O102eS102eS101 106.94(15)
O3a-S2-S1 105.41(18) O103eS102eS101 106.58(17)
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modiﬁcation has a dramatic effect on the cytotoxicity of these
compounds in cells. This suggests that the toxicity of these com-
pounds is primarily determined by the phosphonium cation itself
rather than by the alkylthioacetate group. This observation is in
Fig. 7. (a) Molecular packing in 3 and (b) with the interaction between adjacent phenyl rings highlighted. The distance between the centres of the phenyl rings is 3.65 Å.
Fig. 8. Ortep representation of the molecular structure of 4. Thermal ellipsoids are drawn at 50% probability level.
Table 2
Selected Bond Lengths (Å) and angles () in 4.
P1eC1 1.783(5) P101eC101 1.790(5)
P1eC7 1.792(5) P101eC107 1.796(5)
P1eC13 1.788(5) P101eC113 1.802(5)
P1eC19 1.808 (4) P101eC119 1.804(5)
S1eC21 1.793(5) S101eC121 1.794(5)
S1eC22 1.771(5) S101eC122 1.767(7)
S1a-C21a 1.689(15)
S1a-C22a 1.762(17)
C4eF1 1.364(6) C104eF011 1.359(6)
C10eF2 1.352(6) C110eF102 1.363(5)
C16eF3 1.357(6) C116eF103 1.371(5)
O1eC22 1.193(7) O101eC122 1.211(8)
O1aC22a 1.197(17)
C1eP1eC7 109.8(2) C101eP101eC107 108.2(2)
C1eP1eC13 109.2(2) C101eP101eC113 111.8(2)
C1eP1eC19 109.8(2) C101eP101eC119 110.4(2)
C7eP1eC13 109.3(2) C107eP101eC113 111.1(2)
C7eP1eC19 110.9(2) C107eP101eC119 108.3(2)
C13eP1eC19 107.7(2) C113eP101eC119 107.0(2)
C21eS1eC22 100.5(3) C121eS011eC122 101.3(3)
C21eS1aC22a 110.8(9)
Fig. 9. Molecular packing in 4.
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agreement with work reported by Smith and co-workers [29], who
showed that the maximum tolerated acute dosage for a series of
phosphonium compounds, inwhich triphenylphosphonium groups
were conjugated to a range of very different molecular entities,
were broadly similar.
Rideout et al., and Cheng et al., have previously reported the use
of MALDI-TOF-MS to measure the cellular uptake of phosphonium
compounds by cancer cell lines. Both studies highlighted the high
speciﬁcity and sensitivity of the technique for the quantiﬁcation of
phosphonium compounds and the reproducibility of the data.
Furthermore, phosphonium compounds have also been used to
derivatise proteins [30], and other molecules [31], to improve their
detection by mass spectrometry. As well as the difference in cyto-
toxicity, there is a notable difference in the rate of cellular uptake
and level of accumulation of compounds 2 and 4, the tri-
ﬂuorophenyl derivative being taken-up at lower levels, and at a
slower rate than the triphenyl derivative. Similar results were
observed by Cheng et al. who found that the 4-
ﬂuorophenyl(triphenyl)phosphonium cation [(4-FC6H4)PPh3
þ] was
taken-up by C6 glioma cells more slowly, and at only 80% of the
levels, of the tetraphenylphosphonium cation [Ph4P
þ].
The poor solubility of the phosphonioalkylthiosulfate zwitter-
ions 1 and 3 was disappointing. A number of different solvents
including toluene, THF, methanol, acetone and PBS, cell culture
media and b-cyclodextrin, which is widely used in the pharma-
ceutical industry to enhance drug solubility [32], were investigated.
However, none of these proved suitable for dissolving the zwit-
terions for cell biology experiments. It is interesting to note that
phosphonium-functionalised gold nanoparticles derived from
zwitterions 1 and 3 are soluble in aqueous media [7]. Cheng et al.
observed that (4-carboxybutyl)triphenylphosphonium bromide,
which is a zwitterion under physiological conditions, is accumu-
lated only very minimally by cells and was not detectable in MALDI
experiments [18]. The poor solubility of 1 and 3 is likely to be linked
to the strong non-covalent interactions between adjacent mole-
cules. In addition to electrostatic attractions, 3 displays offset face-
to-face phenyl embrace interactions between phenyl rings in
adjacent molecules, which are a common feature of the propeller
arrangement of phenyl rings in phosphonium and related com-
pound [33], together with intermolecular F/H hydrogen bonding
interactions. These intermolecular interactions serve to stabilise
the molecules. The u-thioacetylpropyl(triaryl)phosphonium salts 2
and 4, are soluble in a range of solvents. The crystal structure of 4
shows that this compound does not display the phenyl embrace
interactions seen in 2. Furthermore, the F/H hydrogen bonds in 4
are weaker than those in 2 and the complex web of intermolecular
interactions in 4 are focused around the bromide anions and waters
of crystallisation. This may explain why this compound, and the
phenyl analogue 3, show much greater solubility than the
zwitterions.
4. Conclusion
The results show that the u-thioacetylpropyl(triaryl)phospho-
nium salts are readily taken-up by cells and can be quantiﬁed using
MALDI-TOF-MS. The phosphonium salts show low cyctoxicity
compared with other triphenylphosphonium compounds, making
them potentially useful species for transporting other species, such
as metal nanoparticles, into cells. The phosphoniopropylthiosulfate
zwitterions are not soluble in aqueous solutions or other solvents
which are compatible with biological testing. Crystallographic
analysis of the tri(4-ﬂuorophenyl)phosphoniopropylthiosulfate
zwitterion (3) reveals an extensive array of electrostatic and non-
covalent intermolecular interactions which may serve to reduce
the solubility of this and related zwitterions in aqueous media.
5. Experimental
5.1. Synthesis of 1 - 4
Chemicals and solvents were purchased from Sigma-Aldrich or
Fisher Scientiﬁc Ltd and used as received. All 1H, 31P and 19F NMR
spectra were recorded on a Brucker AVANCE III (400 MHz). IR
spectra were recorded on a Brucker ALPHA platinum ATR spec-
trometer. Melting points were determined on a Stuart SMP3
melting point apparatus and are uncorrected. Electrospray Ionisa-
tion Mass spectrometry was performed on a Thermo Finnigan LCQ
classic in positive ion mode.
The synthesis and spectroscopic data of triphenylphosphonio-
propylthiosulfate (1) and u-thioacetylpropyltriphenyl-phospho-
nium bromide (2) have been reported previously [9,10].
Tri(4-ﬂuorophenyl)phosphoniopropylthiosulfate (3) and u-thi-
oacetylpropyl(tri-4-ﬂuorophenyl)phosphonium bromide (4) were
prepared from (tri-4-ﬂuorophenyl)phosphine as described below:
Tris(4-ﬂuorophenyl)phosphine (1.0 g, 3.16  103 mol) and 3-
bromo-1-propanol (1.1 mL, 1.25  102 mol) were reﬂuxed in
acetonitrile (20 mL) under nitrogen overnight to yield 3-
hydroxypropyl(tri-4-ﬂuorophenyl)phosphonium bromide. Upon
completion the reaction mixture was diluted with deionised water
(20 mL) and the product isolated by liquid-liquid extraction using
dichloromethane (3  20 mL). The dichloromethane extracts were
combined, dried over MgSO4, and the solvent removed by rotary
evaporation. The 3-hydroxypropyl(tri-4-ﬂuorophenyl)phosponium
bromide was reﬂuxed with HBr (48%, 10 mL) under nitrogen
overnight. Upon completion the reaction mixture was diluted by
the addition of deionised water (20 mL) and the product, 3-
bromopropyl(tri-4-ﬂuorophenyl)phosphonium bromide, sepa-
rated by liquid-liquid extraction using dichloromethane
(3  20 mL). The dichloromethane extracts were combined, dried
over MgSO4, and the solvent removed by rotary evaporation,
yielding 3-bromopropyl(tri-4-ﬂuorophenyl)phosphonium bromide
as a white solid. To produce zwitterion 3, 3-bromopropyl(tri-4-
ﬂuorophenyl)phosphonium bromide (0.250 g, 5.70  104 mol)
and Na2S2O3 (0.212 g, 8.56  10
4 mol) were reﬂuxed in aqueous
ethanol. The thioacetate salt 4was produced by stirring together 3-
Fig. 10. Hydrogen bonding in the crystal structure of 4. Thermal ellipsoids are drawn at
50% probability level.
Table 3
Hydrogen bonds in 4 [Å and ].
DH/A d(H/A) d(DH) d(/A) :(DHA)
O2eH2A/ Br1 0.937(16) 2.445(19) 3.347(4) 162(3)
O2eH2B/ Br1i 0.842(17) 2.510(16) 3.349(4) 175(5)
O3eH3A/Br2ii 0.963(16) 2.356(18) 3.296(4) 165(7)
O3eH3B/Br2iii 0.860(17) 2.36(3) 3.141(4) 151(4)
Symmetry transformations used to generate equivalent atoms: (i) x,yþ1/2,z1/2
(ii) xþ1,y,z (iii) xþ1,yþ1,z.
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bromopropyl(tri-4-ﬂuorophenyl)phosphonium bromide (0.250 g,
5.70  104 mol) and KSC(O)CH3 (0.098 g, 8.56  10
4 mol) in
aqueous ethanol. Both compounds were isolated from the reaction
mixtures by extraction with dichloromethane (3  20 mL). Puriﬁ-
cation of the products, which form as white microcrystalline
powders, was achieved by triturating with diethyl ether and
recrystallising from dichloromethane/diethyl ether. The progress of
all of the reactions was monitored by TLC using a mobile phase of
80% dichloromethane: 20% methanol.
Analytical data for compounds 3 and 4 are reported here for the
ﬁrst time:
Tri(4-ﬂuorophenyl)phosphoniopropylthiosulfate 3 M.p. 243 C;
Elemental analysis: found: C, 53.89; H, 3.93; C21H18F3O3PS2 re-
quires: C, 53.61; H, 3.86.1HNMR (CDCl3) ¼ 2.2 (2H, m), 3.3 (2H, m),
3.6 (2H, m), 7.6e8.0 ppm (15H, m). 31P NMR (CDCl3)¼ 23.3 ppm.
19F
NMR (CDCl3) ¼ 99.3 ppm; FT-IR:nmax/cm
11209 (S]O). Accurate
mass analysis: found 471.0474 [M]þ; cation C21H18F3O3PS2 requires
433.471.0465[M]þ; u-thioacetylpropyl(tri-4-ﬂuorophenyl)phos-
phonium bromide 4 M.p. 118 C; Elemental analysis: found: C,
52.47%; H, 4.09%; C23H21F3SOPBr þ H2O requires: C, 51.97%; H,
4.33%.1H NMR (CDCl3) ¼ 1.9 (5H, m), 3.2 (2H, m), 4.3 (2H, m),
7.3e8.1 (12H, m) ppm.31P NMR (CDCl3) ¼ 23.9 ppm;
19F NMR
(CDCl3) ¼ 99.0 ppm; FT-IR:nmax/cm
11680 (C]O); Accurate mass
analysis: found 433.0976[M]þ; cation C23H21F3SOPBr requires
433.1003[M]þ;
5.2. Cell culture
Human prostate cancer cells (PC3) obtained from ATCC were
maintained in complete media (cDMEM) which contains Dulbec-
co's modiﬁed Eagle mediumwith GlutaMAX, 4.5 g/L D-Glucose and
sodium pyruvate (Invitrogen Life Technologies, Paisley, Renfrew-
shire, UK) containing 10% heat-inactivated fetal bovine serum
(Biosera, East Sussex, Sussex, UK) and 100 I.U/ml Penicillin and
100u ¼ g/ml Streptomycin (Invitrogen Life Technologies Paisley,
Renfrewshire, UK) at 37 C in 5% CO2 and 95% air. Cells were sub-
cultured every 3 days and routinely screened for Mycoplasma Spp.
5.3. Cytotoxicity assay
Cytotoxicity was assessed using CellTiter-Glo™ luminescent cell
viability assay kit (Promega Corporation, Southampton, Hampshire,
UK). PC3 cells were seeded in opaque-walled 96-well plates at a
density of 10,000 cells/well and allowed to adhere overnight. Cells
were subsequently treated with the corresponding phosphonium
compound (0e1000 mM) for 24, 48 and 72 h. After each incubation
period cell viability was measured according to the manufacturer's
instructions; plates were equilibrated at room temperature for
30 min, 100 mL of assay reagent was added to each well, placed on
an orbital shaker for 2 min, left to stand at room temperature for
10 min and read on a Wallac Victor2 1420 multilabel counter
(PerkinElmer, Cambridge, Cambridgeshire, UK). All measurements
were performed in quadruplicate, 3 independent experiments were
conducted (n ¼ 12). All plates contained the following control
wells: control 1 - cells plus cDMEM only, control 2 - cells plus
cDMEM with 0.1% DMSO, control 3 e cells plus cDMEM with 0.01%
DMSO and control 4 - cells plus cDMEM with 0.001% DMSO. Data
are expressed as a percentage of live cells normalised to control, the
average, standard deviation and IC50 values were plotted and
calculated using GraphPad Prism (GraphPad software, La Jolla,
California, USA).
5.4. Cellular uptake studies of phosphonium compounds by MALDI-
MS
Matrix-assisted laser desorption ionisation mass spectrometry
(MALDI-MS) and laser desorption ionisation mass spectrometry
(LDI-MS) experiments were performed in positive ion mode on an
applied Biosystems/MDS Sciex hybrid quadrupole time-of-ﬂight
mass spectrometer (Q-Star Pulsar-i) with an orthogonal MALDI
ion source (Applied Biosystems, Foster City, California, USA) and a
high repetition Neodymium-doped yttrium vandate (Nd: YVO4
laser (5 KHz)) (Elforlight Ltd, Daventry, Northamptonshire, UK).
Spectra were collected with an acquisition time of 1 min. Uptake
studies of phosphonium compounds by MALDI were conducted
using the method reported previously by Cheng et al.[18].
5.5. Calibration curve of phosphonium compounds for semi-
quantiﬁcation analysis by MALDI-MS
PC3 cells were cultured in T75 ﬂasks; after trypsinsation, the
cells were washed twice with PBS (Invitrogen Life Technologies,
Paisley, Renfrewshire, UK), re-suspended in deionised H2O to lyse
the cells and aliquoted at a density of 3.5  106 cells/mL. Phos-
phonium compounds and internal standards were dissolved in
methanol and diluted with PC3 cell lysate to make various con-
centrations and stored at 4 C. 10 mL of phosphonium compound
and 10 mL of internal standard weremixed thoroughly; sequentially
10 mL of this solution was mixed with 10 mL of matrix (DHB or a-
CHCA) and 0.5 mL of sample was deposited on the target MALDI
plate. MALDI matrices (DHB or a-CHCA) were made to a concen-
tration of 10 mg/mL in 70:30 acetonitrile:water with 0.1% tetra-
ﬂuoroacetic acid. Triplicate standards were prepared and analysed;
standards collected from 3 independent cell lysates were prepared
for each study.
5.6. Sample preparation of phosphonium compounds for semi-
quantiﬁcation analysis by MALDI-MS
PC3 cells were cultured in T75 ﬂasks; after trypsinsation, the
cells were washed with PBS twice, re-suspended in low Kþ HEPES
buffer (NaCl, 135 mM, KCl 5 mM, CaCl2 1.8 mM, MgSO4 mM, HEPES
50 mM, dextrose 5.5 mM, pH 7.4) and aliquoted at a density of
10  106 cells/mL. For cellular uptake studies, PC3 cells
(0.5  106 cells/50 mL) were incubated with 10 mL of 100 mM stock
solution of corresponding phosphonium salt (ﬁnal concentration,
5 mM) and 140 mL of low Kþ HEPES buffer and incubated between
0 and 120 min at 37 C. Subsequent to each incubation period, cells
were centrifuged (500  g, 4 min) and washed twice in cold PBS.
Cell pellets were then lysed with 150 mL of cold DIH2O and placed
on dry ice. Prior to MALDI analysis, samples were thawed and
centrifuged (12,000  g, 5 min). The sample cell lysate (90 mL) and
10 mM (10 mL) of the internal standard were mixed together, sub-
sequently 10 mL of this solutionwas mixed with 10 mL of matrix and
0.5 mL of samplewas deposited on the target MALDI plate. Triplicate
samples were prepared and analysed, samples collected from 3
independent cell lysates were prepared for each study.
6. X-ray crystallography
X-Ray crystallographic data of 3 and 4 were collected on a
Bruker APEXII CCD diffractometer mounted at the window of a
Bruker FR591 rotating anode (MoKa, l ¼ 0.71,073 Å) and equipped
with an Oxford Cryosystems Cryostream device. Data were pro-
cessed using the COLLECT package [34] and unit cell parameters
were reﬁned against all data. An empirical absorption correction
was carried out using SADABS [35]. Crystal structure was solved by
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direct methods using SHELXS-97 and reﬁned on Fo
2 by full-matrix
least-squares reﬁnements using SHELXL-97 (3) and SHELXL-2014
(4) [36].
All non-hydrogen atoms were reﬁned with anisotropic
displacement parameters. All hydrogen atoms were added at
calculated positions and reﬁned using a ridingmodel with isotropic
displacement parameters based on the equivalent isotropic
displacement parameter (Ueq) of the parent atom, except those on
O2 and O3 in 4, where DFIX and DANG restraints were used to
maintain appropriate geometry.
In the crystal structure of 3, the eSO3 group is disordered over
two positions with approximately 88:12 ratio (the minor compo-
nent is reﬁned isotropically). In the crystal structure of 4, the
eCH2SCOCH3 group is disordered over two sites with approxi-
mately 91:09 ratio with SIMU, DELU and RIGU restraints applied to
the disordered atoms. Graphics were generated using OLEX2 [37]
and MERCURY [38]. The corresponding CIF has been deposited
with the Cambridge Crystallographic Data Centre.
Crystallographic data of 3: a ¼ 9.4169(13), Å, b ¼ 15.279(3) Å,
c ¼ 16.090(3) Å, a ¼ 73.281(7), b ¼ 77.619(10) , g ¼ 73.052(9);
V ¼ 2099.2(6) Å3, triclinic, P-1, Z ¼ 4, (Z’ ¼ 2), rcalc ¼ 1.489 Mg/m
3;
m ¼ 0.377 mm¡1; T ¼ 120(2) K; qmax ¼ 27.48, 40,825 measured
reﬂections, 9403 unique reﬂections [Rint ¼ 0.1243], 4672 with
F2 > 2s, R(F, F2 > 2s) ¼ 0.0830; Rw(F
2, all data) ¼ 0.2039,
GoF ¼ 1.035, CCDC: 1,474,049.
Crystallographic data of 4: a ¼ 14.8827(3) Å, b ¼ 31.9320(5) Å,
c ¼ 10.6385(2) Å, a ¼ 90, b ¼ 108.9170(10), g ¼ 90;
V ¼ 4782.71(15) Å3, Monoclinic, P21/c, Z ¼ 8, rcalc ¼ 1.476 Mg/m
3;
m ¼ 1.914 mm¡1; T ¼ 120(2) K; qmax ¼ 25.00, 78,770 measured
reﬂections, 8401 unique reﬂections [Rint ¼ 0.0811], 6738 with
F2 > 2s, R(F, F2 > 2s) ¼ 0.0727; Rw(F
2, all data) ¼ 0.2018,
GoF ¼ 1.031, CCDC: 1,474,050.
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